Enovis (C520) AI Stock Analysis

Enovis

(Frankfurt:C520)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Organic growth and share gainsPositive organic growth across both segments, particularly in Reconstruction, indicates continued demand and commercial execution. Growth in hips, knees, shoulders, and extremities, together with reported share-gain opportunities, can support durable revenue expansion over the next several quarters.

Negative Factors

Large ongoing net lossesVery large reported losses remain the clearest fundamental weakness and indicate that revenue growth has not yet translated into consistent GAAP earnings power. Until profitability improves materially, Enovis may have less resilience to operational setbacks and less capacity to fund expansion from earnings.

Enovis (C520) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.15B
Dividend Yield: ―
Average Volume (3M): 140
Price to Earnings (P/E): -1.0
Beta (1Y): 0.99
Revenue Growth: -2.27%
EPS Growth: -19.34%
Country: Germany
Employees: 7,802
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Enovis Business Overview & Revenue Model

Company Description

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic speci...

Enovis Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:-24.81%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call was broadly positive. Enovis delivered 5% organic growth, strong U.S. Recon and new-product momentum, improved margins, higher adjusted EPS, a significant improvement in free cash flow, and progress on deleveraging while reaffirming 2026 guidance. The principal challenges were inflation, tariffs, Middle East-related disruption, softer Western European markets, and a seasonally more difficult third quarter, but management expressed confidence in commercial execution and second-half acceleration.

Positive Updates

Strong Second-Quarter Organic Growth

Second-quarter sales were $583 million, up 3% versus the prior year on a reported basis and up 5% organically. Days-adjusted organic growth was 4% at the enterprise level, 5% in Recon, and 3% in P&R, in line with guidance.

Negative Updates

Middle East Conflict Created Growth and Cost Headwinds

The ongoing conflict in the Middle East negatively affected international businesses, creating a 100 basis point growth headwind internationally and approximately a 40 basis point headwind to total Enovis growth in the quarter. The conflict also contributed to higher raw material, freight, and distribution costs.

Company Guidance

Enovis is reaffirming its 2026 guidance, including free cash flow conversion of greater than 25% in 2026; the $8 million benefit from the partial tariff refund is expected to be offset by $10 million of full year impact from the increased inflationary environment. The company expects the third quarter to have a heavier impact by seasonality than in prior years, with a more seasonally soft Q3 than what we have seen in the past, zero impact year-over-year from selling days, and greater pressure from Western Europe and the conflicts in the Middle East; it expects sales acceleration across both segments in the fourth quarter, with one day in Q4 in terms of selling day impact, as new products scale and launch against improving market volumes. New products are expected to start contributing more as we get into the later part of the year, and the company expects continued adoption in shoulders as we move through the second half of 2026. For 2027, the margin algorithm and cash algorithm are still intact, while the company’s goal is to get leverage down below three here this year.

Enovis Risk Analysis

Enovis disclosed 45 risk factors in its most recent earnings report. Enovis reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks

1.Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity SecuritiesQ2, 2026

2.Item 3. Defaults Upon Senior SecuritiesQ2, 2026

3.Item 5. Other InformationQ2, 2026

Enovis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:C520 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNN	74Outperform	$12.41B	19.52	12.25%	2.67%	5.26%	31.02%
SYK	71Outperform	$111.95B	30.88	15.61%	1.21%	7.87%	22.82%
ZBH	69Neutral	$18.03B	22.89	6.36%	1.02%	8.62%	0.09%
CNMD	67Neutral	$1.32B	18.30	7.07%	―	1.93%	16.93%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IART	44Neutral	$991.96M	75.98	1.24%	―	0.84%	―

* Healthcare Sector Average

Performance Comparison

DE:C520 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:C520	Enovis Corporation	20.00	-6.80	-25.37%
CNMD	Conmed Corporation	44.29	-0.57	-1.27%
IART	Integra Lifesciences	12.75	1.26	10.97%
SNN	Smith & Nephew Snats	29.70	-6.13	-17.11%
SYK	Stryker Corp	291.86	-62.38	-17.61%
ZBH	Zimmer Biomet Holdings	94.52	-4.30	-4.35%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Enovis AI Stock Analysis